Author:
Heerema Nyla A.,Byrd John C.,Dal Cin Paola S.,Dell’ Aquila Marie L.,Koduru Prasad R.K.,Aviram Ayala,Smoley Stephanie A.,Rassenti Laura Z.,Greaves Andrew W.,Brown Jennifer R.,Rai Kanti R.,Kipps Thomas J.,Kay Neil E.,Van Dyke Daniel L.
Subject
Cancer Research,Genetics,Molecular Biology
Reference30 articles.
1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Geneva: World Health Organization; Lyon: IARC Press, 2008
2. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy;Byrd;J Clin Oncol,2006
3. Genomic aberrations and survival in chronic lymphocytic leukemia;Döhner;N Engl J Med,2000
4. Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders;Lin;J Clin Oncol,2010
5. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions;Lozanski;Blood,2004
Cited by
45 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献